Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

Patent metadata

Field	Value
Publication number	US-11723972-B2
Application number	US-201916573374-A
Country	US
Kind code	B2
Filing date	Sep 17, 2019
Priority date	Nov 13, 2009
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

First claim

What is claimed is:

1. A method of detecting the presence or level of a human galectin 1 (Gal1) polypeptide said method comprising obtaining a sample comprising protein from a human subject and detecting said polypeptide in the sample by use of at least one monoclonal antibody, or antigen-binding fragment thereof, that specifically binds Gal1 and comprises six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 consists of residues 31-35 of SEQ ID NO: 7, CDR-H2 consists of residues 50-66 of SEQ ID NO: 7, CDR-H3 consists of residues 99-107 of SEQ ID NO: 7, CDR-L1 consists of residues 23-36 of SEQ ID NO: 9, CDR-L2 consists of residues 52-58 of SEQ ID NO: 9, and CDR-L3 consists of residues 91-99 of SEQ ID NO: 9.

2. The method of claim 1 , wherein the at least one monoclonal antibody or antigen-binding fragment thereof forms a complex with a Gal1 polypeptide and the complex is detected in the form of an enzyme linked immunosorbent assay (ELISA), radioimmune assay (RIA), or immunochemically.

3. The method of claim 1 , wherein
the monoclonal antibody, or antigen-binding fragment thereof, comprises the heavy chain variable domain sequence of SEQ ID NO: 7.

4. The method of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises the light chain variable domain sequence of SEQ ID NO: 9.

5. The method of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises the heavy chain variable domain sequence of SEQ ID NO: 7 and the light chain variable domain sequence of SEQ ID NO: 9.

6. The method of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is a humanized antibody, chimeric antibody, a Fab fragment, a F(ab′) 2 fragment, an Fv fragment, a diabody, or a bispecific antibody.

7. The method of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, comprises an immunoglobulin heavy chain constant domain selected from the group consisting of IgG, IgA, IgM, and IgE constant domains.

8. The method of claim 1 , wherein the monoclonal antibody, or antigen-binding fragment thereof, is conjugated to an agent selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

Assignees

• Dana Farber Cancer Inst Inc
• Brigham & Womens Hospital Inc
• Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
• Fund Sales

Inventors

• Shipp Margaret
• Ouyang Jing
• Takeyama Kunihiko
• Kutok Jeffery L
• Rodig Scott J
• Rabinovich Gabriel
• Russo Diego Omar Croci
• Salatino Mariana

Classifications

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• A61K2039/505

  comprising antibodies · CPC title